MAPT and amyloidosis: Although prior studies have emphasized the association between p‐tau217 with early amyloid pathology, our findings suggest that p‐tau217–based plasma biomarkers may also reflect tau burden in later Braak stage regions, emphasizing their utility not only for early detection of AD but also for staging and disease monitoring across the AD continuum, as suggested in previous studies.35, 36